Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

April 30, 2014

Conditions
HematuriaBladder Cancer
Interventions
DRUG

Valproic Acid

500 mg orally, once daily for up to 30 days

Trial Locations (1)

13210

SUNY Upstate Medical University, Syracuse

All Listed Sponsors
lead

State University of New York - Upstate Medical University

OTHER

NCT01738815 - Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer | Biotech Hunter | Biotech Hunter